PHARMACEUTICAL COMPOSITION CONTAINING IDEBENONE FOR THE TREATMENT OF LIVER DISORDERS
The invention describes the use of an injectable form of Idebenone to protect against hepatic damage, improve recovery from liver trauma, poisoning, vapor intoxication, degenerative diseases, hepatocyte function loss and pathology associated with inflammation or infection. The use of injectable Idebenone restores liver function, suppresses elevated enzyme levels, decreases alcoholic and drug abuse associated syndromes, symptoms of acute hepatitis of various origins, the consequences of liver reperfusion and other signs of liver damage.
1 . A method of prevention or treatment of liver disorders and ameliorating diseases and conditions associated with liver damage; said method comprises the parenteral administration of pharmaceutical compositions, comprised of at least one physiologically acceptable derivative of 1,4-benzoquinone.
2 . A method as set forth in claim 1 wherein said composition is a derivative of 1,4-benzoquinone is 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (Idebenone).
3 . A method as set forth in claim 1 wherein said composition is administrated parenterally via intravenous injection, intravenous infusion, intra-arterial, intramuscular, subcutaneous or intraperitoneal injection.
4 . A method as set forth in claim 1 wherein said derivative of 1,4-benzoquinone is administrated in doses ranging from 0.5 to 50 mg/kg per day.
5 . A method as set forth in claim 1 wherein said composition is incorporated in a colloidal delivery system, whose components are selected from micellar preparations, emulsions, liposomes, solid lipid nanoparticles, polymeric nanoparticles, nanocapsules or suspensions, wherein said 1,4-benzoquinone derivative is associated with a hydrophobic phase of the colloidal system.
6 . A method as set forth in claim 5 wherein said emulsion is an oil-in-water emulsion.
7 . A method as set forth in claim 1 wherein said liver disorder is caused by trauma.
8 . A method as set forth in claim 1 wherein said liver disorder is caused by poisoning.
9 . A method as set forth in claim 1 wherein said liver disorder is caused by apoptosis.
10 . A method as set forth in claim 1 wherein said liver disorder is associated with mitochondrial dysfunction.
11 . A method as set forth in claim 1 wherein said liver disorder is caused by non-steroidal analgesics or antipyrexics.
12 . A method as set forth in claim 1 wherein said liver disorder is caused by ethanol.
13 . A method as set forth in claim 1 wherein said liver disorder is caused by antibiotics.
14 . A method as set forth in claim 1 wherein said liver disorder is caused by drug abuse.
15 . A method as set forth in claim 1 wherein said liver disorder is caused by halogenated hydrocarbons.
16 . A method as set forth in claim 1 wherein said liver disorder is associated with liver damage caused by protozoal, fungal, bacterial or viral infections.
17 . A method as set forth in claim 16 wherein said liver disorder is caused by hepatitis virus of type A, B, C, D, E, G.
18 . A method as set forth in claim 1 wherein said liver disorder is caused by acute hepatitis or acute liver failure.
19 . A method as set forth in claim 1 wherein said liver disorder is caused by an inhalational anesthetic agent.
20 . A method as set forth in claim 11 wherein said liver disorder is caused by paracetamol/acetaminophen compounds.
21 . A method as set forth in claim 11 wherein said liver disorder is caused by salicylate, acetylsalicylate or metamizole.
22 . A method as set forth in claim 13 wherein said liver disorder is caused by isoniazid.
23 . A method as set forth in claim 13 wherein said liver disorder is caused by tetracyclines.
24 . A method as set forth in claim 19 wherein said liver disorder is caused by isoflurane, desflurane, enflurane or sevoflurane.
25 . A method as set forth in claim 1 wherein said liver disorder is caused by liver reperfusion and liver transplantation.
26 . A method as set forth in claim 1 wherein said liver disorder is caused by acute alcoholic intoxication.
27 . A method as set forth in claim 1 wherein said liver disorder is caused by steroid hormones.
28 . A method as set forth in claim 1 wherein said liver disorder is caused by aflatoxins or aflastatins.
29 . A method as set forth in claim 1 wherein said liver disorder is caused by cholestasis or cholecystitis.
30 . A method as set forth in claim 1 wherein said liver disorder associated with an increase in alanyl aminotransferase and aspartate aminotransferase levels.